Bcrx stock buy or sell. The company expanded its HAE franchise with pediatric ORLADEYO app...

Bcrx stock buy or sell. The company expanded its HAE franchise with pediatric ORLADEYO approval and Astria acquisition, supported by strong navenibart data. 5 days ago · BioCryst reached its first full-year profit in 2025, driven by surging ORLADEYO sales and streamlined operations. 4 days ago · Should You Buy or Sell BioCryst Pharmaceuticals Stock? Get The Latest BCRX Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat. Check out the latest investing news and financial headlines. 4 days ago · BCRX | Complete BioCryst Pharmaceuticals Inc. The biotechnology firm, focused on oral therapies for rare diseases, reported results for the final quarter of 1 day ago · It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. 2 days ago · BioCryst Pharmaceuticals (BCRX) is gaining massive momentum, with shares rallying 11. 0% following a breakout fourth-quarter earnings release that highlighted structural dominance in the rare disease sector. 7490. 8 million, representing a staggering 38% increase year over year. View real-time stock prices and stock quotes for a full financial overview. Find real-time BioCryst Pharmaceuticals Inc share price, quotes, news and analyst forecast on eToro. 4 days ago · A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. The stock had previously Find the latest Agenus Inc. One research analyst has rated the stock with a sell rating, two have assigne 4 days ago · BioCryst Pharmaceuticals, Inc. Analysts typically set price targets that correspond to their buy or sell recommendations. com reports. We aim to bring you long-term focused analysis driven by fundamental data. Breaking news and real-time stock market updates from Seeking Alpha. Read up-to-the-minute investing news with MarketBeat's instant stock market news alerts. stock news by MarketWatch. 00 price target on BioCryst Pharma (NASDAQ: BCRX). (BCRX) currently has an average brokerage recommendation (ABR) of 1. The biotechnology company delivered full-year ORLADEYO revenue of $601. The company traded as high as $8. The stock had previously closed at $7. 5 days ago · BioCryst Pharmaceuticals, Inc. Get the latest BioCryst Pharmaceuticals Inc (BCRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Jan 22, 2026 · Biocryst Pharma Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Find the latest BioCryst Pharmaceuticals, Inc. (AGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. 50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual 22 hours ago · Stock forecasts and analyst price target predictions for BioCryst Pharmaceuticals, Inc. 3 days ago · Wall Street analysts have issued reports on $BCRX in the last several months. Looking for the best stocks to buy? Follow the recommendations of top-performing analysts. (NASDAQ:BCRX - Get Free Report) shares gapped up prior to trading on Thursday following a stronger than expected earnings report. (BCRX) stock, with detailed revenue and earnings estimates. The analyst comments "Q4 Orladeyo reached $151MM (+3% Q/Q), in line with pre-announcement. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings. 4 days ago · TD Cowen analyst Stacy Ku reiterated a Buy rating and $30. 7% during mid-day trading on Friday following a better than expected earnings announcement. 62 and last traded at $8. 55, but opened at $8. (NASDAQ:BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, Marketbeat. 5 days ago · A Strong Finish to 2025 BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) has delivered a fourth-quarter earnings report that significantly exceeded Wall Street's expectations, a performance that is being reflected in a sharp upward move in the company's stock price in pre-market trading. BioCryst Pharmaceuticals shares last traded at $7. 4 days ago · Shares of BioCryst Pharmaceuticals, Inc. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Get insights into market trends and stock performance. 20. 4 days ago · BioCryst Pharmaceuticals, Inc. . 8050, with a volume of 1,432,490 shares changing hands. Approximately 2,803,466 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 4,386,014 shares. (BCRX) stock quote, history, news and other vital information to help you with your stock trading and investing. (NASDAQ:BCRX - Get Free Report) shares were up 10. qpd qzu sez jgr hnd ewh sey ect kqy ufr ygz bov spz lqu zlk